Drug intelligence / Profile preview

Dyspro

Development stage: Preclinical
Lead developer: Eve Health
Modality: Small Molecules
Administration: Buccal, Oral

Overview

**Dyspro** is Eve Health's proprietary prescription medicinal-cannabis pastille for oral use. The commercially supplied formulation contains the cannabinoids cannabidiol, cannabigerol, and cannabinol in a fixed-dose pastille intended to dissolve in the mouth. Eve Health markets Dyspro in Australia for dysmenorrhoea and endometriosis-related pain through the Therapeutic Goods Administration Special Access Scheme Category B pathway; it is an unapproved therapeutic good and is not listed on the Australian Register of Therapeutic Goods. ([evehealthgroup.com.au](https://evehealthgroup.com.au/documents/dyspro-cmi.pdf))

Brand names: Dyspro
Other names: Dyspro CBD35:CBG25:CBN15 PastillesDyspro PastillesEVE Dyspro medicinal cannabis pastilles

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on Dyspro.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dyspro.

Explore the full profile